Single mothers children do well as those of two-parent | WeForNews | Latest News, Blogs Single mothers children do well as those of two-parent – WeForNews | Latest News, Blogs
Connect with us

Health

Single mothers children do well as those of two-parent

Published

on

single mothers

London, July 6: Children born to single women without a partner appeared to enjoy similarly as those in two-parent families, researchers say.

Single mother by choice is an increasingly popular procedure in most European countries.

According to the study, no major change was seen like emotional involvement or parental stress between family types and the same with the child, no problem with internal and external problem behaviour.

Single-mothers-by-choice, however, showed significantly higher scores on the social support such as parents, other family, friends, neighbours.

“Single-mothers-by-choice and their children benefit from a good social support network, and this should be emphasised in the counselling of women who want to have and raise a child without a partner,” said Mathilde Brewaeys from the VU University Medical Centre.

Experts had raised concerns about the well-being and development of children born to single-mothers-by-choice.

However, it seems single mother children can grow properly and the negative influence on child development depends more on a troubled parent-child relationship, researchers said.

“The assumption that growing up in a family without a father is not good for the child is based mainly on research into children whose parents are divorced and who thus have experienced parental conflict,” Brewaeys explained.

For the study, the team compared 69 single-mothers-by-choice (who had knowingly chosen to raise their child alone) and 59 mothers from heterosexual two-parent families with a child between 1.5 and 6 years.

Wefornews Bureau

Cities

We’ve resources to undertake coronavirus vaccination within 3-4 weeks: Delhi govt

Health and Family Welfare Minister Satyendar Jain made this announcement in at a press conference called to update Delhi’s daily health bulletin.

Published

on

By

Vaccine Covid

The Delhi government on Saturday said it has infrastructure to undertake coronavirus vaccination among all city residents within three-four weeks, adding that it was only waiting for the vaccine to be made available.

Health and Family Welfare Minister Satyendar Jain made this announcement in at a press conference called to update Delhi’s daily health bulletin. He gave the updates on Covid-19, decreasing positivity rate, availability of beds, and preparations for vaccination.

He said that the government had enough resources like Mohalla Clinics, polyclinics, dispensaries and hospitals to administer coronavirus vaccine across Delhi. Jain asserted that there will be no issues about the optimal storage of the vaccine as well.

“We are only waiting for the vaccine to be made available. Delhi has the infrastructure to roll it out and make it accessible to all city residents within 3-4 weeks. Delhi is equipped with the latest infrastructure to facilitate the rollout of the vaccine to Delhi’s population.

“For application, there are Mohalla Clinics, hospitals etc. It depends on how soon we get it from the central government. As far as storage is concerned, all amenities have been taken care of,” Jain said.

The Delhi government’s response comes amid Prime Minister Narendra Modi’s Saturday visit to Ahmedabad, Hyderabad and Pune where vaccine development process is going on.

Modi had recently held discussions with states and union territories on vaccine distribution once it is formulated.

Pointing out that there were 5,482 new cases in Delhi on Friday, the Minister said that the positivity rate had however come down to 8.51 per cent from 15.26 per cent. It has become less than half since November 7, 2020.

The Minister said that more than 50 per cent beds for coronavirus patients are available in Delhi hospitals at present. “Total bed available is more than 9,500. The occupancy rate is therefore steadily decreasing. In terms of ICU beds, more than 1,200 are available.”

Continue Reading

Health

SII to seek emergency use authorisation for AstraZeneca Covid vaccine in 2 weeks: Poonawalla

Published

on

Adar Poonawalla

New Delhi: The Serum Institute of India (SII) will seek emergency use authorisation for the AstraZeneca Covid 19 vaccine in about two weeks.

Adar Poonawalla, Founder and CEO, SII said on Saturday that SII is in the process of submitting the data for the clinical trials to the DCGI and will seek emergency use authorisation.

He said there will be no delays in the AstraZeneca vaccine rollout as the trials are more than enough for establishing efficacy and it will not affect emergency use authorization in Europe and certainly not in India. There was a recent error in dosage during trials which AstraZeneca is trying to correct, as per reports.

“What we might have to do is trials for under 18 candidates. That is way all vaccines go. You first have to establish safety for adults and then go for studies on the impact on children,” he added.

Speaking after Prime Minister Narendra Modi’s visit to the SII facility in Pune, Poonawalla said PM Modi discussed in detail the vaccination scenario and reviewed the vaccine production status.

“Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility,” PM Modi said in a tweet.

He said 50-60 per cent of the world’s vaccines are made in India and with Atmanirbhar Bharat in mind, SII today showcased the largest pandemic facility at their facility in in Pune.

He added that the implementation plan for the AstraZeneca and Oxford vaccine, Covishield will be clear only after emergency use authorisation is received. SII is in the process of submitting to DCGI. There are plans to roll out hundreds of millions of doses in the second quarter but only after all regulatory approvals are received.

He said so many different vaccines were discussed with PM Modi and their logistical and pricing issues. As of now, there is nothing in writing from the Indian government but Health Ministry has announced a target of 300-400 million doses by July 2021, which SII is scaling up for, he added.

SII is in the process of applying of emergency use licence in two weeks. It will be distributed in India initially and then the Covax countries of Africa.

On the other vaccine, Novavax, where SII has a tie up, Poonawalla said it is two months behind Astrazeneca and the same process will be followed in terms of trials and approvals.

The third one, Codagenics is way behind and will take at least a year to get into licence stage. It is only starting stage 1 trials in UK in December so that will take a year, Poonawalla said.

He said both these vaccines can be stored at temperatures of 2-8 celsius for which India has a lot of capacity. He said that for vaccines which much lower temperatures India’s capacity for storage is negligible.

SII is currently producing 50-60 million doses a month which by January-February will be scaled up to 100 million doses a month.

Issues about how to distribute and where to distribute the vaccine will become clear after the vaccine gets emergency use authorisation which will take a few weeks to happen, Poonawalla added.

He added that a delayed approval in UK does not have much impact as stock piling and manufacturing is going on and a delay of a couple of weeks will not make much impact.

The AstraZeneca vaccine has shown zero hospitalization and reduced the virus by 60 per cent. So those who got infected were not passing it on and there was no severe attack of coronavirus requiring hospitalisation.

Continue Reading

Health

PM reviews vaccine progress at Serum Institute in Pune

Published

on

Modi for Vaccine

Pune, Nov 28: Prime Minister Narendra Modi on Saturday evening visited the Serum Institute of India (SII) here, which is currently in the process of developing the much-anticipated Covid-19 vaccine.

The Prime Minister went around the plant premises accompanied by senior officials of the company, who explained the details of the vaccine manufacturing process.

“Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility,” Modi tweeted after his visit, and shared pictures.

The Prime Minister went on a flying visit to three cities on Saturday to check the progress of the vaccines being developed to immunise people against coronavirus.

Earlier in the day, he had visited the Bharat Biotech facility in Hyderabad, preceded by a trip to the Zydus Biotech Park in Ahmedabad.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.